OTLK
NASDAQOutlook Therapeutics Inc.
News · 26 weeks73+15%
2026-03-012026-08-23
Mix4590d
- SEC Filings21(47%)
- Insider12(27%)
- Other6(13%)
- Offering4(9%)
- Analyst1(2%)
- Earnings1(2%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by Outlook Therapeutics Inc.SCHEDULE 13G - Outlook Therapeutics, Inc. (0001649989) (Subject)
- SECSEC Form 10-Q filed by Outlook Therapeutics Inc.10-Q - Outlook Therapeutics, Inc. (0001649989) (Filer)
- SECSEC Form NT 10-Q filed by Outlook Therapeutics Inc.NT 10-Q - Outlook Therapeutics, Inc. (0001649989) (Filer)
- INSIDERChief Executive Officer Jahr Robert Charles bought 151,515 shares (SEC Form 4)4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)
- INSIDERDirector Sukhtian Ghiath M. bought $2,499,999 worth of shares (2,525,252 units at $0.99) (SEC Form 4)4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)
- INSIDERChief Financial Officer Kenyon Lawrence A bought 101,010 shares, increasing direct ownership by 1,699% to 106,956 units (SEC Form 4)4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)
- SECOutlook Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)
- SECSEC Form 424B5 filed by Outlook Therapeutics Inc.424B5 - Outlook Therapeutics, Inc. (0001649989) (Filer)
- SECOutlook Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)
- PROutlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™The only FDA-approved ophthalmic bevacizumab, LYTENAVATM, addresses a significant need in the U.S. wet AMD market where bevacizumab is already widely used Advancing the U.S. launch strategy for LYTENAVA, including broad market access, reimbursement, pricing, medical affairs, and supply capabilities Potential to exceed $500 million in annual U.S. LYTENAVA sales by 2030 Company to host corporate update conference call today, August 14th, at 8:30 AM ET — registration details below ISELIN, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab
- PROutlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and WarrantsISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) ("Outlook Therapeutics"), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced the pricing of an underwritten public offering of 55,555,556 shares of its common stock and accompanying warrants to purchase up to an aggregate of 55,555,556 shares of its common stock. The combined public offering price of each share of common stock and accompanying warrant to purchase one share is $0.99. The accompanying warrants have an exercise price of $1.10 per share, will become exercisabl
- SECSEC Form 424B5 filed by Outlook Therapeutics Inc.424B5 - Outlook Therapeutics, Inc. (0001649989) (Filer)
- SECOutlook Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)
- PROutlook Therapeutics Announces Proposed Public Offering of Common Stock and WarrantsISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) ("Outlook Therapeutics"), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants to purchase shares of its common stock. Outlook Therapeutics also intends to grant the underwriters a 30-day option to purchase additional shares of its common stock and/or accompanying warrants in an amount up to fifteen percent (15%) of the shares of its common stock and/or accompanying warrants o
- PROutlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026ISELIN, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it will report its financial results for the third quarter fiscal year 2026 and will host a corporate update conference call and webcast on Friday, August 14, 2026, at 8:30 AM ET. The call will be hosted by members of Outlook Therapeutics’ leadership team, Bob Jahr, Chief Executive Officer, and Lawrence A. Kenyon, Executive Vice President and Chief Financial Officer. Interested participants and investors may access
- INSIDERDirector Sukhtian Faisal Ghiath bought $99,996 worth of shares (95,398 units at $1.05), increasing direct ownership by 76% to 220,972 units (SEC Form 4)4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)
- FDAFDA Approval for LYTENAVA issued to OUTLOOK THERAPEUTICS, INC.Submission status for OUTLOOK THERAPEUTICS, INC.'s drug LYTENAVA (ORIG-1) with active ingredient BEVACIZUMAB-VIKG has changed to 'Approval' on 07/24/2026. Application Category: BLA, Application Number: 761320, Application Classification:
- ANALYSTOutlook Therapeutics upgraded by BTIG Research with a new price targetBTIG Research upgraded Outlook Therapeutics from Neutral to Buy and set a new price target of $4.00
- SECOutlook Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)
- PROutlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMDLandmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an Ophthalmic Bevacizumab Developed Specifically for the Eye Following Years of Rigorous Clinical and Regulatory Evaluation Company Launches Commercial Franchise Positioned to Establish a New Standard as an FDA-Approved Bevacizumab Therapy Across the Approximately $8.5 Billion U.S. Retina Market Anticipated 12 Years of Market Exclusivity Under the Biologics Price Competition and Innovation Act (BPCIA) ISELIN, N.J., July 24, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bev
- SECSEC Form 8-K filed by Outlook Therapeutics Inc.8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Kenyon Lawrence A4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Jahr Robert Charles4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)
- SECSEC Form EFFECT filed by Outlook Therapeutics Inc.EFFECT - Outlook Therapeutics, Inc. (0001649989) (Filer)
- SECSEC Form 424B3 filed by Outlook Therapeutics Inc.424B3 - Outlook Therapeutics, Inc. (0001649989) (Filer)
OTLK FAQ
7 questionsWhat does Outlook Therapeutics Inc. do?
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical...Where does OTLK stock trade?
Outlook Therapeutics Inc. (OTLK) is listed on NASDAQ.What sector and industry is OTLK in?
Outlook Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Outlook Therapeutics Inc. go public?
Outlook Therapeutics Inc. (OTLK) completed its IPO in 2016.What are analysts saying about OTLK?
Outlook Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from BTIG Research: Buy with a $400.00 price target on 2026-07-27. Recent price targets range from $300.00 to $400.00.What companies are similar to OTLK?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare OTLK side-by-side with any of them on Quantisnow.How can I track OTLK on Quantisnow?
Quantisnow aggregates Outlook Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OTLK to receive live email and push alerts on every new disclosure.